Vishwas Mishra

Vishwas Mishra

Auto-generated profile, based on publicly available information

Vishwas Mishra

Department of Life Sciences, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
VMVishwas Mishra
Vishwas Mishra
ABAvipsa Bose
Avipsa Bose
SKShashi Kiran
Shashi Kiran
SBSanghita Banerjee
Sanghita Banerjee
ISIdrees A. Shah
Idrees A. Shah
SVSandhya S. Visweswariah
Sandhya S. Visweswariah
Activating mutations in receptor guanylyl cyclase C (GC-C), the target of gastrointestinal peptide hormones guanylin and uroguanylin, and bacterial heat-stable enterotoxins cause early-onset diarrhea and chronic inflammatory bowel disease (IBD). GC-C regulates ion and fluid secretion in the gut via cGMP production and activation of cGMP-dependent protein kinase II. We characterize a novel mouse model harboring an activating mutation in Gucy2c equivalent to that seen in an affected Norwegian family. Mutant mice demonstrated elevated intestinal cGMP levels and enhanced fecal water and sodium content. Basal and linaclotide-mediated small intestinal transit was higher in mutant mice, and they were more susceptible to DSS-induced colitis. Fecal microbiome and gene expression analyses of colonic tissue revealed dysbiosis, up-regulation of IFN-stimulated genes, and misregulation of genes associated with human IBD and animal models of colitis. This novel mouse model thus provides molecular insights into the multiple roles of intestinal epithelial cell cGMP, which culminate in dysbiosis and the induction of inflammation in the gut.

20 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
VMVishwas Mishra
Vishwas Mishra
ACAnna Crespo-Puig
Anna Crespo-Puig
CMCallum McCarthy
Callum McCarthy
TMTereza Masonou
Tereza Masonou
IGIzabela Glegola-Madejska
Izabela Glegola-Madejska
ASAvinash R. Shenoy
Avinash R. Shenoy
The cytokine interleukin-1β (IL-1β) has pivotal roles in antimicrobial immunity, but also incites inflammatory disease. Bioactive IL-1β is released following proteolytic maturation of the pro-IL-1β precursor by caspase-1. UBE2L3, a ubiquitin conjugating enzyme, promotes pro-IL-1β ubiquitylation and proteasomal disposal. However, actions of UBE2L3 in vivo and its ubiquitin ligase partners in this process are unknown. Here we report that deletion ofUbe2l3in mice reduces pro-IL-1β turnover in macrophages, leading to excessive mature IL-1β production, neutrophilic inflammation and disease following inflammasome activation. An unbiased RNAi screen identified TRIP12 and AREL1 E3 ligases of the Homologous to E6 C-terminus (HECT) family in adding destabilising K27-, K29- and K33- poly-ubiquitin chains on pro-IL-1β. We show that precursor abundance determines mature IL-1β production, and UBE2L3, TRIP12 and AREL1 limit inflammation by shrinking the cellular pool of pro-IL-1β. Our study uncovers fundamental processes governing IL-1β homeostasis and provides molecular insights that could be exploited to mitigate its adverse actions in disease.

1 May 2018 in Infection and Immunity
Verified
Journal Article
Closed access
SMShamik Majumdar
Shamik Majumdar
VMVishwas Mishra
Vishwas Mishra
SNSomesh Nandi
Somesh Nandi
MAMudabir Abdullah
Mudabir Abdullah
ABAnaxee Barman
Anaxee Barman
SVSandhya S. Visweswariah
Sandhya S. Visweswariah
NontyphoidalSalmonelladisease contributes toward significant morbidity and mortality across the world. Host factors, including gamma interferon, tumor necrosis factor alpha, and gut microbiota, significantly influence the outcome ofSalmonellapathogenesis. However, the entire repertoire of host protective mechanisms contributing toSalmonellapathogenicity is not completely appreciated. Here, we investigated the roles of receptor guanylyl cyclase C (GC-C), which is predominantly expressed in the intestine and regulates intestinal cell proliferation and fluid-ion homeostasis. Mice deficient in GC-C (Gucy2c−/−) displayed accelerated mortality compared with that for wild-type mice following infection via the oral route, even though both groups possessed comparable systemicSalmonellainfection burdens. Survival following intraperitoneal infection remained similar in both groups, indicating that GC-C offered protection via a gut-mediated response. The serum cortisol level was higher inGucy2c−/−mice than wild-type (Gucy2c+/+) mice, and an increase in infection-induced thymic atrophy with a loss of immature CD4+CD8+double-positive thymocytes was observed. Accelerated and enhanced damage in the ileum, including submucosal edema, epithelial cell damage, focal tufting, and distortion of the villus architecture, was seen inGucy2c−/−mice concomitantly with a larger number of ileal tissue-associated bacteria. Transcription of key mediators ofSalmonella-induced inflammation (interleukin-22/Reg3β) was altered inGucy2c−/−mice in comparison to that inGucy2c+/+mice. A reduction in fecal lactobacilli, which are protective againstSalmonellainfection, was observed inGucy2c−/−mice.Gucy2c−/−mice cohoused with wild-type mice continued to show reduced amounts of lactobacilli and increased susceptibility to infection. Our study, therefore, suggests that the receptor GC-C confers a survival advantage during gut-mediatedSalmonella entericaserovar Typhimurium pathogenesis, presumably by regulatingSalmonellaeffector mechanisms and maintaining a beneficial microbiome.

12 November 2018 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
VMVishwas Mishra
Vishwas Mishra
RGRidhima Goel
Ridhima Goel
SVSandhya S. Visweswariah
Sandhya S. Visweswariah
The availability of genome sequence information and a large number of protein structures has allowed the cataloging of genes into various families, based on their function and predicted biochemical activity. Intriguingly, a number of proteins harbor changes in the amino acid sequence at residues, that from structural elucidation, are critical for catalytic activity. Such proteins have been categorized as ‘pseudoenzymes’. Here, we review the role of the pseudokinase (or kinase-homology) domain in receptor guanylyl cyclases. These are multidomain single-pass, transmembrane proteins harboring an extracellular ligand-binding domain, and an intracellular domain composed of a kinase-homology domain that regulates the activity of the associated guanylyl cyclase domain. Mutations that lie in the kinase-homology domain of these receptors are associated with human disease, and either abolish or enhance cGMP production by these receptors to alter downstream signaling events. This raises the interesting possibility that one could identify molecules that bind to the pseudokinase domain and regulate the activities of these receptors, in order to alleviate symptoms in patients harboring these mutations.

2 July 2025 in Gut Microbes
Verified
Journal Article
Open access
PBPriyanka Biswas
Priyanka Biswas
JSJulia Sanchez-Garrido
Julia Sanchez-Garrido
ZKZuzanna Kozik
Zuzanna Kozik
VMVishwas Mishra
Vishwas Mishra
DRDavid Ruano-Gallego
David Ruano-Gallego
GFGad Frankel
Gad Frankel
Injection of effectors via a type III secretion system (T3SS) is an infection strategy shared by various Gram-negative bacterial pathogens, many infecting mucosal surfaces. While individual T3SS effectors are well characterized, their network-level organization and the distinction between core and accessory effectors remain incompletely understood. Here, by systematically dissecting the T3SS effector network of the enteric mouse pathogen Citrobacter rodentium (CR) we identified a subset of 12 accessory effectors that, while dispensable for colonization, significantly alter infection outcomes. A strain lacking the accessory effectors (CRM12) remained virulent in susceptible mouse hosts yet resulted in reduced epithelial barrier damage, inflammation, and immune cell infiltration in resistant mice. Deep proteomic analysis specifically targeting CR-attached colonic epithelial cells revealed that, despite lacking 39% of its effector repertoire, infection with CRM12 results in similar changes to global protein expression as seen in mice infected with the wild-type strain, though key regulators of barrier integrity were differentially expressed. Using a host with impaired barrier repair (Il22- /- mice), we confirmed that accessory effectors collectively shape infection outcomes without significantly impacting virulence. This study refines the concept of core and accessory effectors, providing a basis for further studies into effector-driven host adaptation.

6 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJoshua L. C. Wong
Joshua L. C. Wong
JSJulia Sanchez-Garrido
Julia Sanchez-Garrido
JRJaie Rattle
Jaie Rattle
JBJonathan Bradshaw
Jonathan Bradshaw
VMVishwas Mishra
Vishwas Mishra
GFGad Frankel
Gad Frankel
Existing technologies employed to generate antibodies against bacterial polysaccharides and proteins rely on the availability of purified or synthetic antigens. Here, we present a genetics-based platform that utilises Citrobacter rodentium (CR), an enteric mouse pathogen, to both produce and present complex heterologous polysaccharides and protein antigen complexes during natural infection. As proof of concept, we use lipopolysaccharides (O), capsular polysaccharides (K) and type 3 fimbrial (T3F) antigens expressed by the WHO critical priority pathogens Klebsiella pneumoniae (KP) and Escherichia coli (EC). Following one infection cycle (28 days), CR induces specific IgG antibodies against KPO1, ECO25b, KPK2 and KPT3F. We demonstrate that the antibodies are functional in downstream applications, including protection against pathogenic KP challenge, KP capsular serotyping and KP biofilm inhibition. Whilst KP and EC antigens were used as prototypical examples, this modular platform is now readily adaptable to generate antibodies against diverse polysaccharide and protein antigens, with basic science, public health and therapeutic applications.